相关实验视频

Updated: Sep 16, 2025

Analysis of the c-KIT Ligand Promoter Using Chromatin Immunoprecipitation

Analysis of the c-KIT Ligand Promoter Using Chromatin Immunoprecipitation

Published on: June 27, 2017

工程DNA原始传感器用于TGFβ1封存,以增强瘤免疫调节和治疗

Xiao Chen¹, Dunfang Liu^1,2, Jiahui Jin³

¹Institute of Molecular Medicine and Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, State Key Laboratory of Oncogenes and Related Genes, Renji Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai, 200127, China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|July 11, 2025

概括

研究人员开发了一种DNA原纳米设备,以捕获和清除TGFβ1,增强抗瘤免疫力和T细胞活性. 这种新的方法通过精确调节瘤微环境,对癌症免疫疗法显示出希望.

科学领域:

生物技术是生物技术.
纳米技术纳米技术
免疫学免疫学免疫学

背景情况:

瘤微环境 (TME) 调制对于有效的癌症治疗至关重要.
转化生长因子β1 (TGFβ1) 是TME中的一个关键的免疫抑制细胞因子,使其成为关键的治疗标.

研究的目的:

开发一种基于DNA原形的纳米装置,用于高效地封存和清除TGFβ1.1.
评估纳米设备在增强抗瘤免疫力和T细胞介导的细胞毒性方面的有效性.

主要方法:

具有不同几何形状和孔径的大小的DNA框架捕捉器 (DFC) 的设计和工程.
在体外评估T细胞介导的细胞毒性在存在的DFCs.
用小鼠模型进行体内研究,以评估与PD-L1抗体的瘤生长抑制和协同效应.
免疫组织化学 (IHC) 用于TGFβ1降低和生物分布分析.

主要成果:

一个桶形的DNA框架捕获器 (DBC) 证明了优越的TGFβ1调节效率.
DBCs在体外显著增强了T细胞介导的瘤细胞毒性.
系统性给予DBCs抑制了体内瘤生长,并与PD-L1阻断显示出协同效应.
IHC证实瘤组织TGFβ1水平降低,并提供生物分布数据.

结论:

结构性DNA纳米设备可以合理设计,用于精确的免疫调节.
使用DNA原木纳米设备的TGFβ1封存是一种可行的策略,可以增强癌症免疫疗法.
这种方法为利用TME提高治疗结果提供了一个变革性的工具.

关键词:

基因原始结构框架DNA原始结构框架这是一种TGFβ结合.快速的细胞因子清除系统性免疫调节系统性免疫调节瘤免疫疗法免疫疗法

更多相关视频

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling

Published on: August 3, 2018

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

相关概念视频

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...